Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LeChRO-seq in L3.6pl (Parental and Paclitaxel-resistant)

ABSTRACT: leChRO-seq in L3.6pl (Parental and Paclitaxel-resistant)

PROVIDER: PRJEB52825 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR9725616.fastq.gz	Fastqsanger.gz
	ERR9725617.fastq.gz	Fastqsanger.gz
	ERR9725618.fastq.gz	Fastqsanger.gz

Items per page:

1 - 3 of 3

Similar Datasets

H3K4me3 HiChIP for L3.6pl cells (parental and paclitaxel-resistant)

Project description:H3K4me3 HiChIP for L3.6pl cells (parental and paclitaxel-resistant)

| PRJEB52812 | ENA

leChRO-seq in L3.6pl (Parental and Paclitaxel-resistant)

Project description:Evaluate the nascent RNA-seq production in L3.6pl

2023-03-24 | E-MTAB-11744 | biostudies-arrayexpress

ATAC seq for L3.6pl cells: Parental and resistant to paclitaxel [PacR]

Project description:ATAC seq for L3.6pl cells: Parental and resistant to paclitaxel [PacR]

| PRJEB52808 | ENA

4C-seq at iHUB regions in L3.6pl

Project description:Evaluation of interaction frequency in parental L3.6pl cells, paclitaxel-resistant cells and resistant cells treated with a CDK9 inhibitor

2023-04-21 | E-MTAB-11731 | biostudies-arrayexpress

ChIP seq for H4K5ac, JunD , and MED1 in Parental and Paclitaxel resistant L3.6pl cell line

Project description:ChIP seq for H4K5ac, JunD , and MED1 in Parental and Paclitaxel resistant L3.6pl cell line

| PRJEB60378 | ENA

H3K4me3 HiChIP for Paclitaxel resistant L3.6pl pancreatic cancer cells (Non targeting vs siJunD)

Project description:H3K4me3 HiChIP for Paclitaxel resistant L3.6pl pancreatic cancer cells (Non targeting vs siJunD)

| PRJEB60383 | ENA

Paclitaxel resistant MDA-MB-231 Cells and resensitization with bexarotene treatment

2011-07-19 | GSE12791 | GEO

ChIP seq for H3K27ac, BRD4, H3K4me3, Pol II and input in paclitaxel resistant L3.6pl cells ChIP for Pol II , H3K4me3 and input in parental L3.6pl

Project description:Identification of localization patterns for different histone modifications and transcription activators in parental and resistant cells

2023-04-21 | E-MTAB-11733 | biostudies-arrayexpress

ATAC seq for L3.6pl cells: Parental and resistant to paclitaxel [PacR]

Project description:Identification of open chromatin regions in sensitive and resistant cells

2023-03-21 | E-MTAB-11730 | biostudies-arrayexpress

Paclitaxel resistant MDA-MB-231 Cells and resensitization with bexarotene treatment

Project description:Acquired drug resistance represents a major challenge in chemo-therapy treatment for various types of cancers. We have found that the retinoid X receptorâselective agonist bexarotene (LGD1069, Targretin) was efficacious in treating chemo-resistant cancer cells. The goal of this microarray study was to understand the mechanism of bexaroteneâs role in overcoming acquired drug resistance using human breast cancer cells MDA-MB-231 as a model system and paclitaxel as model compound. After MDA-MB-231 cells were repeatedly treated with paclitaxel for 8 cycles with each cycle including a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium, MDA cells resistant to paclitaxel were developed and their growth was no longer inhibited by paclitaxel treatment. Those MDA cells with acquired drug resistance, when treated with paclitaxel and bexarotene in combination, could regain their sensitivity and their growth were again inhibited. Therefore, RNA samples from parental MDA-MB-231 cells, paclitaxel-resistant MDA cells treated with vehicle, paclitaxel alone or in combination with bexarotene, were used for perform global gene expression profiling with Affymetrix HG-U133A gene chips. Keywords: Drug Treatment MDA-MB-231 cells were exposed to regimens on a 10-day cycle: a 3-day treatment with 30 nM paclitaxel and followed by a 7-day exposure to control medium. Paclitaxel resistant MDA-MB-231 cells (MDA-PR) were established within 8 cycles of such treatment (80 days). These MDA-PR cells were then treated with vehicle control, paclitaxel along, or the combination of 30 nM paclitaxel ( 3 days on and 7 days off) and 1 ÂµM Targretin (10 days on) in a new 10-day cycle for 3 months. Thus, there are four treatment groups, parent MDA cells, MDA-PR, MDA-PR treated with paclitaxel, MDA-PR treated with paclitaxel and bexarotene, and each group had four biological replicates.

2011-07-18 | E-GEOD-12791 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data